When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Gia, a six-year-old with celiac disease, presents with gastrointestinal issues despite avoiding gluten. Stool tests reveal a Giardia infection, and immunoglobulin tests show low IgA and high IgE…
Presented by the Florida Society of Clinical Oncology, this program provides opportunities for patients and caregivers to learn and share information regarding a diagnosis of systemic mastocytosis. Pankit…
Donna, a long-time Huntington Beach resident, shares her journey living with non-small cell lung cancer (NSCLC). Diagnosed with the rare ERBB2 exon 20 mutation, she recounts the initial…
